What Type of Doctor Does a Thyroid Nodule Biopsy?

Thyroid nodule biopsies are performed by several types of doctors, most commonly endocrinologists, interventional radiologists, and surgeons (including head and neck surgeons and ear-nose-throat specialists). There is no single “correct” specialty for the procedure, and research comparing these groups has found similar diagnostic accuracy across them. What matters more than the doctor’s specialty title is their experience with ultrasound-guided needle procedures and the volume of biopsies they perform.

Which Specialists Perform the Procedure

The three specialties you are most likely to encounter are endocrinologists, radiologists, and surgeons. An endocrinologist is typically the doctor who manages your thyroid condition overall, and many of them also perform the biopsy themselves using ultrasound guidance. In one large cytological series, all biopsies were carried out by a single expert endocrinologist with over twenty years of experience in thyroid ultrasound and fine-needle aspiration.¹ Interventional radiologists are imaging specialists who use ultrasound, CT, and other modalities to guide procedures throughout the body; thyroid biopsy is squarely within their wheelhouse.² Head and neck surgeons and ENT (otolaryngology) specialists also perform biopsies, especially when they are already evaluating a patient for potential surgery.

A study comparing nearly 1,900 ultrasound-guided biopsies found no significant difference in non-diagnostic rates between general surgeons and interventional radiologists.³ Another analysis of newly trained head and neck surgeons found their non-diagnostic rate was about 14.5%, compared with roughly 15.4% for radiologists, a difference that was not statistically meaningful.⁴ So the evidence consistently shows that once a doctor is trained in the technique, specialty background does not meaningfully affect biopsy quality.

That said, a nationwide German survey of ENT departments found that roughly half of the responding clinics did not perform either fine-needle aspiration or core needle biopsy at all.⁵ The takeaway is that not every clinic within a given specialty offers the procedure. Whether your biopsy is done by an endocrinologist, a radiologist, or a surgeon often depends on local practice patterns and who has the ultrasound setup available.

Why Ultrasound Guidance Matters More Than the Doctor’s Title

Almost all thyroid biopsies today are done under real-time ultrasound guidance, which lets the doctor watch the needle enter the nodule on a screen. This is a huge improvement over the old approach of feeling for the nodule by hand and inserting the needle blindly. Ultrasound guidance allows precise targeting, but the procedure remains highly operator-dependent.⁶ In practical terms, that means an endocrinologist who performs dozens of biopsies a month with ultrasound will likely get better samples than a surgeon who only does a few per year, and vice versa. When choosing a provider, asking about their biopsy volume is a more useful question than asking about their specialty board certification.

One interesting finding from the surgeon-versus-radiologist comparison was the difference in wait times. The median time from scheduling to actually getting the biopsy was zero days for head and neck surgeons (because they often did it during the same clinic visit) versus six days for radiologists, a statistically significant gap.⁴ If you are seeing a surgeon or endocrinologist who has the equipment in their office, you may be able to get the biopsy done on the spot rather than waiting for a separate radiology appointment.

How the Decision to Biopsy Is Made

Not every thyroid nodule needs a biopsy. Most nodules are benign, and doctors use a scoring system based on what the nodule looks like on ultrasound to decide whether sticking a needle in it is worthwhile. The most widely used system in the United States is the ACR TI-RADS (Thyroid Imaging Reporting and Data System), which assigns points based on features like the nodule’s shape, composition, echogenicity, and margins. The total score places the nodule into a category ranging from TR1 (benign) to TR5 (high suspicion for malignancy).⁷ Only nodules above a certain suspicion level and above a minimum size threshold are recommended for biopsy.

Research has shown that ACR TI-RADS has higher specificity than several other risk stratification systems and reduces unnecessary biopsies of benign nodules by roughly 20% to 47% compared with those other systems.⁸ For small nodules under 2 cm, ACR TI-RADS achieves the highest reduction in unnecessary biopsies among compared systems, though it trades some sensitivity to do so.⁹ The radiologist or endocrinologist who performs your ultrasound will typically apply TI-RADS (or a comparable national guideline) and then discuss whether biopsy is recommended.

Fine-Needle Aspiration Versus Core Needle Biopsy

The standard procedure is a fine-needle aspiration, or FNA. The doctor inserts a very thin needle (typically around 23 gauge, thinner than a standard blood-draw needle) into the nodule, usually making two or more passes to collect enough cells. The sample goes onto slides or into a preservative and is sent to a cytopathologist for examination under a microscope. The whole process takes about 10 to 20 minutes, and most people describe the discomfort as mild.

A core needle biopsy, or CNB, uses a slightly larger needle with a spring-loaded mechanism to cut a small cylinder of tissue. CNB is less commonly performed as a first-line procedure, but it has a clear advantage when FNA comes back inconclusive. A meta-analysis of eleven studies found that core needle biopsy was far less likely to produce a non-diagnostic result: the risk of getting an unreadable sample was about 73% lower with CNB compared to FNA.¹⁰ For nodules that had already had one non-diagnostic FNA, the advantage was even stronger. A direct comparison study found that CNB had a non-diagnostic rate of only about 3% versus 11% for FNA, and CNB also produced fewer ambiguous “gray zone” results.¹¹

CNB tends to shine particularly with nodules classified in the intermediate-suspicion range and with nodules larger than 2 cm, where it produces more conclusive results than FNA.¹² Despite these advantages, FNA remains the default first step at most institutions because it is simpler, cheaper, and carries marginally fewer complications. CNB is typically reserved for cases where FNA has failed to provide a clear answer.

The Hidden Team Member: The Pathologist

No matter which doctor wields the needle, the person who actually reads the sample and determines what it means is a pathologist or cytopathologist. This specialist examines the cells under a microscope and classifies the findings using the Bethesda System for Reporting Thyroid Cytopathology, which sorts results into six categories. In a large institutional review, about 69% of samples came back as clearly benign, roughly 4% were clearly malignant, and the rest fell into various intermediate categories ranging from non-diagnostic to suspicious.¹³

At some centers, a cytopathologist or cytotechnologist is physically present during the biopsy to evaluate the slides in real time, a practice called rapid on-site evaluation, or ROSE. The idea is simple: if the sample is not adequate, the doctor can immediately take another pass rather than sending you home and scheduling a repeat procedure weeks later. A meta-analysis found that ROSE boosted sample adequacy from about 76% to 92%.¹⁴ Another study reported that the rate of non-diagnostic and ambiguous results dropped from about 40% without ROSE to roughly 4% with it.¹⁵

The benefit of ROSE is greatest at centers where the baseline non-diagnostic rate is already high, often because less experienced operators are performing the biopsies. At centers that already have low non-diagnostic rates, ROSE adds only a modest improvement.¹⁴ Not every facility offers ROSE because it requires a pathologist to be available during the procedure, which adds staffing costs. If you have already had one non-diagnostic biopsy and need a repeat, asking whether the next one will include on-site evaluation is reasonable.

What Happens When Results Are Unclear

About 15% to 20% of thyroid biopsies come back in a gray zone: not clearly benign, not clearly malignant. These are the Bethesda III and IV categories, sometimes called “indeterminate cytology.” In the past, many of these patients went straight to surgery just to get a definitive answer, even though most of those nodules turned out to be benign after the thyroid was removed. Molecular testing has changed this picture considerably.

Several commercially available molecular tests can analyze the biopsy sample for genetic mutations and gene expression patterns associated with thyroid cancer. A randomized trial comparing two leading approaches (an RNA-based test and a combined DNA-RNA test) found sensitivities of 100% and about 97%, with specificities around 80% and 85%, respectively.¹⁶ In plain terms, these tests are very good at catching cancer when it is present, and reasonably good at correctly identifying benign nodules, which means fewer patients need diagnostic surgery. A health technology assessment concluded that molecular testing for indeterminate nodules can reduce unnecessary surgeries.¹⁷

The decision to order molecular testing usually involves both the pathologist (who identifies the sample as indeterminate) and the managing clinician, whether that is an endocrinologist or a surgeon. One multicenter study found that a significantly higher proportion of Bethesda IV nodules tested positive on molecular analysis compared with Bethesda III nodules, and consequently more Bethesda IV patients were referred for surgery.¹⁸ This is worth knowing because if your biopsy lands in an indeterminate category, molecular testing is often the next logical step before anyone discusses surgery.

Safety and What the Procedure Feels Like

Thyroid FNA is one of the safest procedures in medicine. A systematic review of 23 studies found that most patients experience no discomfort or only mild discomfort. The most common complication is a small hematoma (a bruise from collected blood under the skin), which occurred in 0% to about 6% of patients depending on the study. Vasovagal reactions (feeling faint), temporary voice changes, and accidental tracheal puncture are all rare. The extremely unusual complication of tumor cells seeding along the needle track was reported in only about 0.02% to 0.19% of cases.¹⁹

Core needle biopsy carries slightly higher complication rates because of the larger needle, but they are still low. A retrospective study of over 6,100 patients who had CNB found an overall complication rate of about 0.8%, with only four major complications out of thousands of procedures.²⁰ For most people, the worst part is the anticipation. A prospective study found that patients’ anxiety levels before the biopsy were significantly linked to how much pain they perceived and even to the likelihood of getting a non-diagnostic sample, possibly because anxious patients tense up and move more.²¹

One area of genuine uncertainty is what to do about blood thinners. A survey of providers found wide variation in practice: only about 13% held low-dose aspirin before the procedure, while roughly 73% held warfarin.²² Guidelines do not give a firm universal recommendation here, so if you take blood-thinning medications, the safest move is to ask the specific doctor performing your biopsy about their protocol. Most will still proceed with aspirin on board but may ask you to pause stronger anticoagulants for a day or two. Patients with known bleeding disorders deserve special attention, as rare but serious hematomas have been reported in this group.²³

Thyroid Nodule Biopsy in Children

The criteria for biopsying thyroid nodules in children differ from those in adults. Nodule size plays less of a role in deciding whether to biopsy a pediatric nodule, partly because children have higher malignancy rates in thyroid nodules overall.²⁴ The adult TI-RADS thresholds tend to underperform in this population, missing a substantial number of cancers. A recent study proposed pediatric-specific biopsy cutoffs that lowered the size threshold for suspicious nodules, which improved sensitivity from about 60% to 84% for the ACR TI-RADS system and reduced the missed-malignancy rate.²⁵

Children with thyroid nodules are typically managed by pediatric endocrinologists, and the biopsy may be performed by a pediatric radiologist or the endocrinologist themselves. Sedation is sometimes used for younger children who cannot stay still during the procedure. If your child has a thyroid nodule, a referral to a center with pediatric thyroid expertise is especially worthwhile, because the clinical decision-making around when to biopsy and how to interpret results differs enough from adult practice that adult-focused guidelines can lead to missed diagnoses.

Reducing Anxiety During the Procedure

Given that anxiety can worsen both the experience and the sample quality, some centers have experimented with distraction techniques. One quasi-experimental study tested virtual reality glasses during the biopsy and found that anxiety dropped significantly in the group that used them. About 78% of participants said they would want VR glasses again if they needed a repeat biopsy, and the same proportion said they would recommend the experience to others facing the procedure.²⁶ VR during biopsies is still more novelty than standard practice, but it highlights a real point: anything that keeps you calm and still during the five to ten minutes of needle work helps both your comfort and the quality of the sample. Slow breathing, listening to music through earbuds, or simply looking away from the ultrasound screen are low-tech versions of the same idea. Asking the doctor to talk you through each step before they do it can also help, since the moments that catch people off guard (the sting of a numbing injection, the pressure of the needle advancing) are less distressing when you know they are coming.